VivoSeq
Psychiatry

Methamphetamine

2

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

Methamphetamine is an early-stage landscape with 2 programs across 2 companies. The most active players are Lykos Therapeutics, InterveXion Therapeutics, LLC.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

L

Lykos Therapeutics

0 programs

PreclinicalI

InterveXion Therapeutics, LLC

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 12

S-(+)-Methamphetamine

University of Wisconsin, Madison

R-(-)-Methamphetamine

University of Wisconsin, Madison

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

45

clinical trials

Completed30 · 67%
Unknown status5 · 11%
Withdrawn4 · 9%
Recruiting2 · 4%
Terminated2 · 4%
Not yet recruiting2 · 4%

Clinical Trials

Trial Activity

45 trials

Methamphetamine and Troriluzole
Recruiting·—·Phase 1·NCT06989853·40 enrolled
Psilocybin for Methamphetamine Addiction
Recruiting·—·Phase 1·NCT06899594·20 enrolled
Glutide for Ending Methamphetamine
Not yet recruiting·SSan Francisco Department of Public Health·Phase 2·NCT07204249·162 enrolled
The Low-Down on Methamphetamine Isomers: Prevalence and Pharmacology in Humans
Not yet recruiting·UUniversity of Wisconsin, Madison·Phase 1·NCT06746831·17 enrolled
Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
Completed·—·Phase 1·NCT04178993·8 enrolled
Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose
Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT05809271·25 enrolled
Factors Affecting Methamphetamine and Opiates Drug Testing
Completed·National Institute on Drug Abuse (NIDA)·Phase 1·NCT01736332·29 enrolled
Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)
Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT00990067·16 enrolled
Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction
Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT03527316·30 enrolled
Study of Naltrexone for Methamphetamine Addiction
Completed·—·Phase 2·NCT00984360·22 enrolled
Mirtazapine and Methamphetamine Drug-drug Interaction Study
Completed·SSan Francisco Department of Public Health·Phase 1·NCT04614584·15 enrolled
Safety Interaction Trial Ibudilast and Methamphetamine
Completed·UUniversity of California, Los Angeles·Phase 1·NCT01217970·11 enrolled
Acquisition of Responses to a Methamphetamine-associated Cue in Healthy Humans
Completed·UUniversity of Chicago·N/A·NCT02323048·90 enrolled
Study of Medical Treatment for Methamphetamine Addiction
Completed·UUniversity of California, Los Angeles·Phase 2·NCT00833443·84 enrolled
Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM
Completed·—·Phase 2·NCT04791969·60 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)